IRIS
FRANCINI, GUIDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.990
EU - Europa 9.003
AS - Asia 1.784
SA - Sud America 29
AF - Africa 24
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 15
Totale 21.867
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.949
GB - Regno Unito 2.476
IE - Irlanda 1.629
CN - Cina 1.260
UA - Ucraina 1.211
SE - Svezia 902
RU - Federazione Russa 666
DE - Germania 613
FR - Francia 596
IT - Italia 457
SG - Singapore 328
FI - Finlandia 290
VN - Vietnam 64
IN - India 38
CA - Canada 37
ES - Italia 37
NL - Olanda 26
BE - Belgio 23
TR - Turchia 21
AU - Australia 18
CI - Costa d'Avorio 18
EU - Europa 15
CL - Cile 13
HK - Hong Kong 12
BR - Brasile 11
CZ - Repubblica Ceca 11
DK - Danimarca 10
IR - Iran 10
PL - Polonia 10
JP - Giappone 8
RO - Romania 8
BG - Bulgaria 5
TW - Taiwan 5
BD - Bangladesh 4
HU - Ungheria 4
NZ - Nuova Zelanda 4
AM - Armenia 3
AR - Argentina 3
AT - Austria 3
CY - Cipro 3
ID - Indonesia 3
IL - Israele 3
IM - Isola di Man 3
OM - Oman 3
PK - Pakistan 3
PT - Portogallo 3
SA - Arabia Saudita 3
TH - Thailandia 3
AZ - Azerbaigian 2
BY - Bielorussia 2
BZ - Belize 2
CH - Svizzera 2
GR - Grecia 2
HR - Croazia 2
LA - Repubblica Popolare Democratica del Laos 2
MA - Marocco 2
MC - Monaco 2
MW - Malawi 2
RS - Serbia 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
EC - Ecuador 1
EE - Estonia 1
EG - Egitto 1
IS - Islanda 1
JM - Giamaica 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
KZ - Kazakistan 1
LB - Libano 1
LT - Lituania 1
LV - Lettonia 1
MD - Moldavia 1
MX - Messico 1
MY - Malesia 1
NG - Nigeria 1
PE - Perù 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 21.867
Salva come PNG Salva come JPEG
Città #
Southend 2.226
Fairfield 1.656
Dublin 1.613
Chandler 1.011
Jacksonville 993
Ashburn 903
Woodbridge 846
Wilmington 687
Seattle 655
Houston 613
Cambridge 520
Nanjing 365
Ann Arbor 358
Princeton 333
Beijing 259
New York 230
Singapore 222
Siena 156
San Mateo 155
Boardman 137
Nanchang 122
San Diego 97
Moscow 89
Helsinki 86
Dong Ket 61
Hebei 53
Shenyang 53
Shanghai 47
Kunming 46
Norwalk 45
Tianjin 43
Changsha 41
Jiaxing 35
Málaga 32
Lancaster 29
Toronto 29
Munich 27
Ningbo 25
Hangzhou 24
Los Angeles 24
Brussels 23
Düsseldorf 21
Fremont 21
London 21
Milan 21
San Francisco 21
Menlo Park 20
Zhengzhou 19
Jinan 18
Abidjan 17
Washington 17
Amsterdam 16
Auburn Hills 16
Philadelphia 14
Redwood City 14
Frankfurt am Main 12
Kansas City 12
Hounslow 11
Izmir 11
Changchun 10
Dallas 10
Dearborn 10
Lanzhou 10
Renton 10
Brno 9
Tappahannock 9
Edinburgh 8
Falls Church 8
Guangzhou 8
Kilburn 8
Santiago 8
Warsaw 8
Delhi 7
Florence 7
Hong Kong 7
Melbourne 7
Paris 7
Rome 7
Taizhou 7
Venezia 7
Fuzhou 6
San Jose 6
Sydney 6
Taastrup 6
Tokyo 6
Chicago 5
Mestre 5
Prescot 5
Santa Clara 5
Sofia 5
Vijayawada 5
Catania 4
Haikou 4
Hyderabad 4
Kocaeli 4
Madrid 4
Reggio Calabria 4
Saint Petersburg 4
São José 4
Udine 4
Totale 15.539
Salva come PNG Salva come JPEG
Nome #
Survival following early-stage colon cancer: An ACCENT-based comparison of patients versus a matched international general population 275
Anti-angiogenetic effects of immune-reconstituted influenza virosomes assembled with parathyroid hormone-related protein derived peptide vaccine. 228
Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer 202
Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey 188
Peptidi epitopici immunogenici del CEA da utilizzare nella chemio-immunoterapia del carcinoma del colon-retto e della mammella. 186
Doxycycline or minocycline may be a viable treatment option against SARS-CoV-2 180
Feasibility of modified docetaxel, oxaliplatin, capecitabine followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancer 172
A62Effectiveness and resulting surgical behavior after neoadjuvant chemotherapy in locally advanced breast cancer: our experience 169
Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma 160
Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer. 158
Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. 151
Folinic Acid and 5-Fluorouracil as adjuvant chemotherapy in colon cancer 150
Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation 150
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer 150
CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab 149
Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience 149
Ecto 5'-nucleotidase in B-cell lymphocytic leukemia 147
Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs. 146
A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid 140
Quality of life in advanced colorectal cancer 140
Bioactivity of GM-CSF and IL-2 in cancer patients 139
Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer. 139
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. 139
Virosoma dell'influenza immunoricostituito (IRIV) contenente il gene per CD40L come immunoprotettore tumorale CEA-specifico e usi immunogenici di esso. 139
70 Tumor associated hypercalcemia 138
Urinary excretion of cyclic adenosine 3',5'-monophosphate and cyclic guanosine 3',5'-monophosphate in malignancy 137
Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients. 137
Circulating levels of immunoreactive peptides and steroid hormones in bronchogenic carcinoma 137
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients with fractioned cisplatinum, oral etoposide and bevacizumab: phase IB/II study 137
A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer 136
Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study 136
Tumour associated antigen (TAA) specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes 135
Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens 135
Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine. 135
The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer 134
Circulating levels of immunoreactive peptides and steroid hormones in bronchogenic carcinoma 134
5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine 134
Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate 133
Pharmacokinetics of intraarterial mitomycin C in hypoxic hepatic infusion with embolization in the treatment of liver metastases 133
Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases 133
Gemcitabine (GEM), 5-fluorouracil (5-FU) and folinic acid (FA) in patients with different gastroenteric malignancies 133
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin 133
Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane 132
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 132
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors 131
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? 130
Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. 129
A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma 129
FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer 128
A five-day treatment of tumor-induced hypercalcemia by intravenous amino-hexane (AHBP) or aminobutane (ABBP) bisphosphonate 128
Is endocrine hyperactivity a favourable prognostic factor in the chemotherapic treatment of bronchogenic carcinoma? 127
Palliative chemotherapy for relief of subocclusive symptoms 126
Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial) 125
Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy 124
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials 124
Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer. 124
Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel 123
Weekly chemotherapy in advanced prostatic cancer 123
Immune-regulatory (FoxP3+)-T-cell tumor infiltration status is predictive of benefit from chemo-immunotherapy with gemcitabine, oxaliplatin, 5FU/FA plus GM-CSF and aldesleukine (GOLFIG) in metastatic colon cancer patients 123
Hepatoid gastric carcinoma. A case report 123
A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity 122
Squamocellular gallbladder carcinoma associated with multiple small pigment stones long term after total gastrectomy 121
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803 121
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. 120
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients 119
Histopathological and prognostic evaluation of immunohistochemical findings in colorectal cancer 119
Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased Raf-1 ubiquitin-dependent degradation 118
Ecto 5'-nucleotidase in B-cell lymphocytic leukemia. 118
Efficacy of Adjuvant Fluorouracil and Folinic Acid in B2 Colon Cancer 118
Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen 117
A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients 117
Weekly low-dose docetaxel in advanced hormone-resistant prostate cancer patients previously exposed to chemotherapy 117
A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate camcer metastates, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2 116
Immune-reconstituted influenza virosome containing CD40L gene enhances the immunological and protective activity of a carcinoembryonic antigen anticancer vaccine 116
Seasonal variation in urinary excretion of cyclic AMP in healthy people 114
Weekly epirubicin in patients with hormone-resistant prostate cancer 114
Weekly chemotherapy in advanced prostatic cancer 114
Folinic acid, 5-fluorouracil and etoposide after curative resection for gastric cancer. 114
Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study 113
Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials 112
Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma 111
In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse 111
Serum osteocalcin concentration in patients with prostatic cancer 110
Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy 110
In vitro generation of cytotoxic T lymphocytes against HLA-A2.1-restricted peptides derived from human thymidylate synthase 110
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients 110
GEMCITABINE (dFdC), 5-FLUROURACIL (5FU), AND FOLINIC ACID (FA) IN THE TREATMENT OF PATIENTS WITH GASTRO-ENTERIC CARCINOMAS: A CLINICAL AND PHARMACOLOGICAL STUDY. 109
Dendritic cell-cediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro 109
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 109
Hyperprogressive disease in advanced cancer patients treated with nivolumab: a case series study 109
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. 108
Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. 107
Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer 107
Hypercalcemia and urinary excretion of cyclic AMP in bronchogenic carcinoma 106
Models of active specific immuno-therapy of human malignancy bone metastases. 106
Osteoblastic metastases: Metabolic and morphologic aspects 106
PTH-rP related peptide cancer therapeutics 105
Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study 105
Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials. 105
PTH-RP related peptide cancer therapeutics. 104
Totale 13.154
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.782
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.782
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.795 0 0 0 0 252 274 330 697 374 432 109 327
2020/20214.016 196 408 98 349 306 588 155 600 482 238 329 267
2021/20222.434 180 310 201 195 103 62 102 97 133 264 243 544
2022/20233.640 240 211 455 543 360 805 62 327 396 59 121 61
2023/20242.336 116 60 171 73 63 771 781 39 3 47 48 164
2024/20251.051 112 286 310 266 77 0 0 0 0 0 0 0
Totale 22.014